Abstract AIMS Brain metastases carry significant morbidity and mortality. The survival of patients with metastatic disease has improved due to systemic therapy advances conferring greater extracranial control. Optimal intracranial local control is probably surgical resection or stereotactic radiosurgery. However, there is a cohort for whom this is inappropriate, either for disease or patient fitness reasons. Traditionally, treatment has included whole brain radiotherapy although this has not been convincingly shown to improve survival or quality of life. AROMA is a single-arm phase II study investigating the feasibility of delivering a novel radiotherapy technique and measuring quality of life. METHOD We have developed a modern technique to deliver dose-escalated internal PTV (DE-iPTV) in patients with metas- tases too large for SRS. Our previously-published planning study demonstrates dosimetric improvements in 5 fractions versus WBRT, with higher lesion dose and lower normal tissue dose. It is delivered using a standard linear accelerator. In AROMA, patients for whom their oncologist would normally consider WBRT instead receive DE-iPTV. QoL measures (EQ5D-3L, Barthel, PS) are collected weekly for 8 weeks then monthly to 6 months. There is an MRI at 6 weeks post-radiotherapy. We are also collecting retrospective observational data on participating centres’ WBRT cohort. RESULTS The primary outcome is completion of treatment and completion of QoL at 8 weeks. Secondary outcomes include lesional response, survival, QoL and steroid use. CONCLUSIONS AROMA is a phase II study looking at the feasibility of DE-iPTV for patients with brain metastases not suitable for SRS or neurosurgery. It is currently in the design and setup phase.
Read full abstract